Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment
Shipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment. British Journal Of Dermatology 2023, 189: 339-341. PMID: 37140007, PMCID: PMC10947518, DOI: 10.1093/bjd/ljad149.Peer-Reviewed Original ResearchConceptsIL-13 expressionBullous pemphigoidImmune-related adverse eventsComplete disease clearancePromising new therapyNovel therapeutic approachesDisease clearanceAdverse eventsTumor immunityTherapeutic approachesNew therapiesConventional treatmentPemphigoidInterleukinTreatmentPatientsExpressionTherapyImmunityClearanceIL17A mRNA Staining Distinguishes Palmoplantar Psoriasis from Hyperkeratotic Palmoplantar Eczema in Diagnostic Skin Biopsies
Chen J, Murphy M, Singh K, Wang A, Chow R, Kim R, Cohen J, Ko C, Damsky W. IL17A mRNA Staining Distinguishes Palmoplantar Psoriasis from Hyperkeratotic Palmoplantar Eczema in Diagnostic Skin Biopsies. JID Innovations 2023, 3: 100189. PMID: 37205304, PMCID: PMC10186614, DOI: 10.1016/j.xjidi.2023.100189.Peer-Reviewed Original ResearchMycosis fungoides palmaris et plantarisPalmoplantar psoriasisNonacral sitesPalmoplantar eczemaMRNA expressionAcral skinIL-13 expressionPalmaris et plantarisDiagnostic skin biopsyDermatopathology databaseIL-17AHistopathologic featuresClinical managementBiopsy specimensSkin biopsiesCytokine biomarkersUseful biomarkerEczemaPsoriasisDiagnostic clarityMRNA stainingDermatosesBiomarkersSitu hybridizationSkin